<PAGE> 1
Prospectus Supplement No. 9 Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated April 3, 2000) Registration No. 333-33252
HUMAN GENOME SCIENCES, INC.
--------------------
$225,000,000
5% Convertible Subordinated Notes Due 2007
and
2,000,000 Shares of Common Stock
Issuable Upon Conversion of the Notes
--------------------
The following information supplements information contained in our
prospectus dated April 3, 2000, relating to the potential offer and sale from
time to time by holders of the notes and the underlying shares of our common
stock. See "Plan of Distribution" in our prospectus.
This prospectus supplement may only be delivered or used in connection
with our prospectus. This prospectus supplement is incorporated by reference
into our prospectus. Our common stock is listed on The Nasdaq National Market
under the symbol "HGSI."
NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR
THE PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
Prospectus Supplement dated October 24, 2000
<PAGE> 2
The notes were originally issued by us and sold by Credit Suisse
First Boston Corporation, as initial purchaser, in a transaction exempt from the
registration requirements of the Securities Act to persons reasonably believed
by the initial purchaser to be qualified institutional buyers or other
institutional accredited investors. Selling holders, including their
transferees, pledgees or donees or their successors, may from time to time offer
and sell any or all of the notes and common stock into which the notes are
convertible.
--------------------
The following table supplements the information in our prospectus
with respect to the selling holders and the principal amounts of notes and
common stock they beneficially own that may be offered under our prospectus. The
information is based on information provided by or on behalf of the selling
holders. All information provided in this prospectus supplement is as of October
23, 2000.
The selling holders may offer all, some or none of the notes or
common stock into which the notes are convertible. Thus, we cannot estimate the
amount of the notes or the common stock that will be held by the selling holders
upon termination of any sales. The column showing ownership after completion of
the offering assumes that the selling holders will sell all of the securities
offered by this prospectus supplement. In addition, the selling holders
identified below may have sold, transferred or otherwise disposed of all or a
portion of their notes since the date on which they provided the information
about their notes in transactions exempt from the registration requirements of
the Securities Act. None of the selling holders has had any material
relationship with us or our affiliates within the past three years, except that
Credit Suisse First Boston Corporation acted as the initial purchaser in
connection with our 5 1/2% Convertible Subordinated Notes Due 2006, 5%
Convertible Subordinated Notes Due 2006, 5% Convertible Subordinated Notes Due
2007, and our 3 3/4% Convertible Subordinated Notes Due 2007 and acted as the
dealer manager in connection with the offer we made to holders of our 5 1/2%
Convertible Subordinated Notes Due 2006. No selling holder named in the table
below beneficially owns one percent or more of our common stock. Common stock
owned prior to the offering and after completion of the offering includes shares
of common stock issuable upon conversion of our 5 1/2% Convertible Subordinated
Notes Due 2006 and 3 3/4% Convertible Subordinated Notes Due 2007.
<TABLE>
<CAPTION>
PRINCIPAL AMOUNT OF NOTES COMMON STOCK OWNED COMMON STOCK OWNED
BENEFICIALLY OWNED AND PRIOR TO THE COMMON STOCK AFTER COMPLETION
NAME OFFERED OFFERING OFFERED OF THE OFFERING
---- ------- -------- ------- ---------------
<S> <C> <C> <C> <C>
Hull Overseas, Ltd. ........... $350,000 5,394 3,111 2,283
</TABLE>
Information concerning the selling holders may change from time to
time and any changed information will be set forth in future prospectus
supplements if and when necessary. Further, the per share conversion price, and
therefore the number of shares of common stock issuable upon conversion of the
notes, is subject to adjustment. As a result, the number of shares of common
stock into which the notes are convertible may increase or decrease.
S - 2
